Short answer
NeuroPace Inc (NPCE) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $23M (down 3.2% year over year) with net income of −$6M.
Q2 2026 key financials · XBRL
- Revenue
- $23M
- −3.2% YoY · +3.1% QoQ
- Net income
- −$6M
- +28.3% YoY · +7.3% QoQ
- Operating margin
- -22.8%
- Gross margin
- 82.9%
- EPS (diluted)
- −$0.18
- +30.8% YoY · +10.0% QoQ
Source: XBRL data from the NeuroPace Inc (NPCE) Q2 2026 10-Q on SEC EDGAR. USD.
NeuroPace Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22.8M, up 17% YoY from $19.5M, driven by higher RNS System unit sales
- Gross margin 82.8% vs 83.1% YoY, reflecting higher material costs partly offset by favorable pricing
- Loss from continuing operations $5.1M vs $8.2M YoY; net loss $6.2M vs $8.7M
- Cash, equivalents and short-term investments $51.7M; outstanding debt $59.0M at June 30, 2026
- FDA deemed PMA-S not approvable; additional information requested for generalized epilepsy label expansion
Risk Factors
- Newly added manufacturing risk: QMSR superseded QSR on February 2, 2026, creating updated compliance requirements
- Most materially updated regulatory risk: FDA staffing changes may delay review of indication-expansion submissions for IGE and ages 12–17
- Compliance risk: Failure to comply with federal and state fraud-and-abuse laws could trigger substantial penalties
- Operational risk: Single-source suppliers Micro Systems Technologies and Integer provide critical components including batteries
- Financial risk: Term Loan Agreement contains financial maintenance covenants, with noncompliance potentially accelerating repayment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NeuroPace Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.